Css LLC Cardiff Oncology, Inc. Call Options Transaction History

Css LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$1.54 - $3.21 $122,276 - $254,874	-79,400 Reduced 67.57%	38,100 $59,000
Q2 2022 Aug 15, 2022	BUY	$1.17 - $2.61 $45,747 - $102,051	39,100 Added 49.87%	117,500 $258,000
Q1 2022 May 16, 2022	BUY	$2.11 - $7.25 $68,364 - $234,900	32,400 Added 70.43%	78,400 $194,000
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $230,460 - $348,680	46,000 New	46,000 $306,000
Q1 2021 May 17, 2021	SELL	$9.1 - $19.57 $152,880 - $328,776	-16,800 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$12.02 - $24.71 $157,462 - $323,701	-13,100 Reduced 43.81%	16,800 $302,000
Q3 2020 Nov 16, 2020	BUY	$4.25 - $14.19 $127,075 - $424,281	29,900 New	29,900 $423,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $184M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.